[ad_1]
Intercept up to 23% pre-market on positive OCA data
Intercept Pharmaceuticals (ICPT) is up 23% pre-market on a low volume after the announcement of positive results from its Phase 3 clinical trial, REGENERA.
View full coverage on Google News
[ad_2]
Source link